NOVABAY PHARMACEUTICALS INC (NBY) Stock Fundamental Analysis

NYSEARCA:NBY • US66987P4090

0.524 USD
-0.06 (-9.81%)
At close: Feb 13, 2026
0.5778 USD
+0.05 (+10.27%)
After Hours: 2/13/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

NBY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. NBY has a bad profitability rating. Also its financial health evaluation is rather negative. NBY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year NBY has reported negative net income.
  • In the past year NBY has reported a negative cash flow from operations.
  • In the past 5 years NBY always reported negative net income.
  • NBY had a negative operating cash flow in each of the past 5 years.
NBY Yearly Net Income VS EBIT VS OCF VS FCFNBY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

  • NBY's Return On Assets of -251.48% is on the low side compared to the rest of the industry. NBY is outperformed by 90.58% of its industry peers.
Industry RankSector Rank
ROA -251.48%
ROE N/A
ROIC N/A
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBY Yearly ROA, ROE, ROICNBY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

  • NBY has a Gross Margin of 66.26%. This is in the better half of the industry: NBY outperforms 75.39% of its industry peers.
  • NBY's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NBY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
NBY Yearly Profit, Operating, Gross MarginsNBY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • NBY does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NBY has more shares outstanding
  • NBY has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, NBY has a worse debt to assets ratio.
NBY Yearly Shares OutstandingNBY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
NBY Yearly Total Debt VS Total AssetsNBY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • NBY has an Altman-Z score of -66.12. This is a bad value and indicates that NBY is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -66.12, NBY is doing worse than 92.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -66.12
ROIC/WACCN/A
WACC9.36%
NBY Yearly LT Debt VS Equity VS FCFNBY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

  • NBY has a Current Ratio of 0.68. This is a bad value and indicates that NBY is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NBY has a Current ratio of 0.68. This is amonst the worse of the industry: NBY underperforms 90.58% of its industry peers.
  • A Quick Ratio of 0.41 indicates that NBY may have some problems paying its short term obligations.
  • The Quick ratio of NBY (0.41) is worse than 90.58% of its industry peers.
Industry RankSector Rank
Current Ratio 0.68
Quick Ratio 0.41
NBY Yearly Current Assets VS Current LiabilitesNBY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • NBY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 84.82%, which is quite impressive.
  • The Revenue for NBY has decreased by -33.58% in the past year. This is quite bad
  • Measured over the past years, NBY shows a quite strong growth in Revenue. The Revenue has been growing by 8.19% on average per year.
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%

3.2 Future

  • NBY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.55% yearly.
  • NBY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.46% yearly.
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NBY Yearly Revenue VS EstimatesNBY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M
NBY Yearly EPS VS EstimatesNBY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2K -4K -6K -8K

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NBY. In the last year negative earnings were reported.
  • Also next year NBY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBY Price Earnings VS Forward Price EarningsNBY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBY Per share dataNBY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NBY's earnings are expected to grow with 31.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.55%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 152.67%, NBY is a good candidate for dividend investing.
  • The stock price of NBY dropped by -49.13% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
  • Compared to an average industry Dividend Yield of 1.18, NBY pays a better dividend. On top of this NBY pays more dividend than 100.00% of the companies listed in the same industry.
  • NBY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.84.
Industry RankSector Rank
Dividend Yield 152.67%

5.2 History

  • NBY does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
NBY Yearly Dividends per shareNBY Yearly Dividends per shareYearly Dividends per share 2025 0.2 0.4 0.6

5.3 Sustainability

DPN/A
EPS Next 2Y31.55%
EPS Next 3YN/A
NBY Yearly Income VS Free CF VS DividendNBY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

More info and screens

Find the best dividend stocksShow peers with best dividend

NOVABAY PHARMACEUTICALS INC

NYSEARCA:NBY (2/13/2026, 8:04:00 PM)

After market: 0.5778 +0.05 (+10.27%)

0.524

-0.06 (-9.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-31
Inst Owners0.99%
Inst Owner Change906.48%
Ins Owners0%
Ins Owner Change0%
Market Cap66.11M
Revenue(TTM)9.78M
Net Income(TTM)-8.61M
Analysts80
Price Target0.87 (66.03%)
Short Float %1.04%
Short Ratio0.66
Dividend
Industry RankSector Rank
Dividend Yield 152.67%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.67%
Min Revenue beat(2)-27.48%
Max Revenue beat(2)-7.85%
Revenue beat(4)0
Avg Revenue beat(4)-20.15%
Min Revenue beat(4)-27.48%
Max Revenue beat(4)-7.85%
Revenue beat(8)2
Avg Revenue beat(8)-7.51%
Revenue beat(12)4
Avg Revenue beat(12)-7.15%
Revenue beat(16)5
Avg Revenue beat(16)-5.76%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.76
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.41
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.08
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -251.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.26%
FCFM N/A
ROA(3y)-178.5%
ROA(5y)-127.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.12%
GM growth 5Y-2.09%
F-Score4
Asset Turnover2.86
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.68
Quick Ratio 0.41
Altman-Z -66.12
F-Score4
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)15.76%
Cap/Depr(5y)29.79%
Cap/Sales(3y)0.32%
Cap/Sales(5y)0.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)84.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.24%
EPS Next Y39.01%
EPS Next 2Y31.55%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-33.58%
Revenue growth 3Y5.12%
Revenue growth 5Y8.19%
Sales Q2Q%-38.05%
Revenue Next Year11.73%
Revenue Next 2Y21.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.57%
OCF growth 3YN/A
OCF growth 5YN/A

NOVABAY PHARMACEUTICALS INC / NBY FAQ

Can you provide the ChartMill fundamental rating for NOVABAY PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 2 / 10 to NBY.


Can you provide the valuation status for NOVABAY PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to NOVABAY PHARMACEUTICALS INC (NBY). This can be considered as Overvalued.


Can you provide the profitability details for NOVABAY PHARMACEUTICALS INC?

NOVABAY PHARMACEUTICALS INC (NBY) has a profitability rating of 1 / 10.


What is the expected EPS growth for NOVABAY PHARMACEUTICALS INC (NBY) stock?

The Earnings per Share (EPS) of NOVABAY PHARMACEUTICALS INC (NBY) is expected to grow by 39.01% in the next year.